Key facts
- Convert Pharmaceuticals’s last known valuation is $8.9M (Jul 2025).
- It has raised $18.5M; the latest was Later Stage VC ($1.1M) in Jul 2025.
- Notable investors include European Innovation Council, Noshaq, Droia Ventures, Eurostars, Walloon Region.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Convert Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Convert Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Convert Pharmaceuticals
Operator of a biotech company intended to produce drugs that augment resistance to conventional anti-cancer treatments. The company's hypoxia-activated drug combines proprietary insights in the tumor micro-environment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs, enabling physicians to treat cancer-affected patient populations in an efficient and swift manner.
- Sector
- Healthcare
- HQ
- Liege, Belgium
- Founded
- 2017
- Employees
- 6
- Website
- convertpharma.com/
- Ownership
- Privately Held (backing)
Convert Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Convert Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Convert Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.